The purpose of the registry is to record incidence of adverse events during treatment with clozapine in patients suffering from bipolar disorder.
Bipolar disorder, with its spectrum, remains a life-long and significant mental health concern due to its unpredictable nature and varied symptomatology. Despite the wide array of available treatments, some cases of bipolar disorder remain resistant to traditional medications. Clozapine, traditionally used for treatment-resistant schizophrenia, has shown promising results in managing resistant cases of bipolar disorder, particularly reducing the risk of suicide. There are not enough controlled studies on clozapine, especially in treatment resistant bipolar depression. There are certain limitations associated with the use of clozapine, primarily related to the possibility of adverse events including agranulocytosis, myocarditis, pneumonia, intestinal obstruction and seizures. Therefore, there is a need for more studies on safety and tolerability of this treatment in patients with bipolar disorder.
Study Type
OBSERVATIONAL
Enrollment
30
Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Age from 18 to 65 years old.
Department of Psychiatry, Medical University of Gdańsk
Gdansk, Pomeranian Voivodeship, Poland
Safety measures of clozapine treatment in patients with bipolar disorder.
Incidence of possible occurrence of adverse events during treatment with clozapine in patients with bipolar disorder.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.